Management of recurrence of hepatitis C infection following liver transplantation

Minerva Chirurgica

Volumn 58, Issue 5, 2003, Pages 717-724

  Charlton, M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatitis C; Liver diseases, etiology; Liver transplantation

Indexed keywords

ALPHA2B INTERFERON; CALCINEURIN INHIBITOR; CORTICOSTEROID; ERYTHROPOIETIN; HEPATITIS C ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2A; RAPAMYCIN; RIBAVIRIN;

ALLOGRAFT; ANEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT FAILURE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; ORGAN DONOR; PASSIVE IMMUNIZATION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RECURRENT INFECTION; REINFECTION; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; VIREMIA;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; PREOPERATIVE CARE; RECURRENCE;

EID: 0348227787     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Boker KH, Daleey G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-10.
2. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
3. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K et al. Severe or multiple rejection episodes are asociated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-4.
4. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-96.
5. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-6.
6. Berenguer J, Prieto M, Mir J, Cordoba J, Rayon M. Hepatitis C viral infection after orthotopic liver transplantation. Adv Exp Med Biol 1994;368:173-9.
7. Barcena R, Del Campo S, Sanroman AL, Nuno J, Zelaya R, Honrubia A et al. Prospective study of hepatitis C virus infection after orthotopic liver transplantation. Transplant Proc 1997;29:515-6.
8. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
9. Berenguer M, Ferrell L, Watson J, Priento M, Kim M, Rayon M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatiol 2000;32:673-84.
10. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77.
11. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000;31:229-37.
12. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-25.
13. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-30.
14. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23:971-6.
15. Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JY. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitter hepatitis C virus infection. Gastroenterology 1994;106:248-51.
16. Dickson RC, Caldwell SH, Ishitani MB, Lau JY, Driscoll CJ, Stevenson TWC et al. Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation. Transplantation 1996;61:701-5.
17. Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, Mondelli M, Zarski JP et al. Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative reverse-transcriptase polymerase chain reaction. Hepatology 1999;29:536-42.
18. Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G et al. Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol 1998;29:1-11.
19. Garcia-Retortillo M, Forns X, Felin A, Moitinho E, Costa J, Navasa M et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7.
20. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999;354:1782-5.
21. Gretch DR, Bacchi CE, Corey L, de la Rosa C, Lesniewski RR, Kowdley K et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995;22:1-9.
22. Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimes. Gut 1999;45:427-34.
23. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-66.
24. Neumann AIJ, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
25. Kakumu S, Takayanagi M, Iwata K, Okumura A, Aiyama T, Ishikawa T et al. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:62-6.
26. Berenguer M, Crippin JS, Gish R, Bass NM, Bostrom A, Netto G et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41.
27. Wiesner RH, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplant 2001;7:442-50.
28. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transplant 2002;8:40-6.
29. Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB jr et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997;63:1419-23.
30. Vargas HE, Laskus T, Wang LF, Radkowski M, Poutous A, Lee R et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplant Surg 1998;4:22-7.
31. Sanchez-Fueyo A, Gimenez-Barcons M, Puig-Basagoiti F, Rimola A, Sanchez-Tapias JM, Saiz JC et al. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001;65:266-75.
32. Sullivan DG, Wilson JJ, Carithers RLJ, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998;72:10036-43.
33. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000;181:1523-7.
34. Cotler SJ, Gaur LK, Gretch DR, Wile M, Strong DM, Bronner MP et al. Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 1998;52:435-43.
35. Prieto M, Nicolas D, Rayon JM, Berenguer M, Carrasco D, Berenguer J. Donor-recipient HLA matching does not predict acceleratef progression of hepatitis C following liver transplantation in genotype 1b patients. Hepatology 2000;32:261A.
36. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10.
37. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen GB, Razonable RR et al. Impact of cytomegolovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplant 2002;8:362-9.
38. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-52.
39. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transplant 2000;6:407-12.
40. Taniguchi M, Wachs M, Bak T, Trotter J. Hepatitis C recurrence in living donor liver transplantation. Am J Transplant 2002;2(Suppl. 3:)138.
41. Ghobrial RM, Amherst F, Farmer DG, Chen P, Anselmo DM, Baquerizo A et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation. Am J Transplant 2002;2(Suppl. 3):163.
42. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transplant Surg 1999;5(4 Suppl 1):107-14.
43. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-6.
44. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV et al. Use of OKT3 is associated with early and severe recurrence of hepatitis c after liver transplantation. Am J Gastroenterol 1997;92:1453-7.
45. Heathcote J, Shiffman ML, Cooksley GW, Dusheiko G, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
46. Crippin JS, McCashlang TM, Terrault NA, Sheiner PA, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplant 2002;8:350-5.
47. Everson GT, Trouillot T, Trottler J, Skilbred J, Halprin A, McKinley C et al. Treatment of decompensated cirrhotics with a low-accelerating dose regime (LADR) of interferon-alfa-2B plus ribavirinn: safety and efficacy. Hepatology 2000;32:308A. Abstract 595.
48. Giostra E, Kullak-Ublick GA, Keller W, Friend R, Kraehenbuhl S, Vanlemmens C et al. Ribavrin/Interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Hepatology 2001;34:641A.
49. Massaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S. Pasquali M et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proceed 1997;29:519-21.
50. Lavezzo B, Rizzetto M, Smedile A, Ottobrelli A, Ghisetti V, Franchello A et al. Combination therapy of interferon alfa 2b and ribavirin for recurrent hepatitis C after liver transplantation. J Hepatol 1999;30:67.
51. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-4.
52. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc. 1997;29:519-21.
53. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002;37:247-52.
54. Menon KVN, Poterucha JJ, El-Amin OA, Burgart LJ, Kremers WK, Rosen C et al. Treatment of post-transplant recurrence of hepatitis C infection with interferon and ribavirin. Lessons on tolerability and efficacy. Liver Transplant 2002;8:515-20.
55. Kapur A, Rodriquez MJ, Schecter P, Tzakis A, Schiff ER. Interferon alfa and ribavirin in established post liver transplant recurrent hepatitis C infection. Gastroenterology 1998;114:A1268.
56. Sameul D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-50.
57. Wasserman R, Brau N, Hassanein T, Bini E, Sulkowski M, Dieterich D. Once weekly Epoetin alfa increases hemogolbin and decreases ribavirin dose reductions among HCV-infected patients who develop anemia on ribavirin/interferon alfa 2b therapy. Hepatology 2000;32:833A.
58. Ferenci P, Peck-Radosavljevic M, Vogel W, Graziadei IW, Riely C, Voight MD et al. 40kDA Peginterferon alfa-2a (Pegasys) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomized multicenter trial. Hepatology 2001;34:406A.
59. Manzarbeitia C, Teperman L, Chalasani N, Sheiner PA, Wiesner R, Marks IM et al. 40kDA Peginterferon alfa-2a (Pegasys) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): Preliminary results of a randomized multicenter trial. Hepatology 2001;34:406A.
60. Vargas HE, Rosati MJ, Douglas DD, Harrison ME, Mulligan DC, Moss AA et al. Combination pagylated interferon alpha-2b and ribavirin in transplant patietns with recurrent hepatitis C infection: A preliminary report. Hepatology 2001;34:407A.
61. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20(4 Pt 1):773-9.
62. Willner IR, Chavin KD, Rogers J, Baliga P, Reuben A. Combination interferon-ribavirin is ineffective and poorly tolerated by liver transplant recipients with genotype 1 recurrent hepatitis C. Hepatology 2000;32:290A.
63. de Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-86.
64. Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998;128:810-6.
65. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L et al. Anti-HCV human immunoglobulin for the prevention of graft infection in HCV-related liver transplantation. A pilot study. J Hepatol 2002;36:32.
66. Belli LS, Zavaglia C, Alberti AB, Poli F, Rondinara G, Silini E et al. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. Hepatology 2000;31:1345-50.
67. Belli LS, Silini E, Alberti A, Bellati G, Vai C, Minola E et al. Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation. Liver Transplant Surg 1996;2:200-5.
68. Gayowski T, Singh N, Marino I, Vargas HE, Wagener MM, Wannstedt CF et al. Hepatitis C virus genotypes in liver transplantat recipients. Transplantation 1997;64:422-6.
69. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-31.
70. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transplantat Surg 1998;4:15-21.
71. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002;35:974-81.